Heartsciences Inc. Reports Minimal Revenues for Q3 2025; Research and Development Expenses Decrease by 19% Compared to Q3 2024
Heartsciences Inc. has released its financial results for the quarter ending July 31, 2025. The company reported revenues of $2,000, an increase from zero in the same period last year. The cost of sales for the quarter was $1,000, resulting in a gross margin of $1,000. Operating expenses decreased by 10% to $1.874 million from $2.076 million in the previous year. This includes a 19% decrease in research and development expenses to $997,000 and a 3% increase in selling, general, and administrative expenses to $878,000. Consequently, the company reported a reduced loss from operations of $1.874 million compared to a loss of $2.076 million in the same quarter last year. The company did not provide any specific outlook or guidance for the future period within the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001468492-25-000010), on September 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。